Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Bladder Cancer, January 2024

Free Subscription


Abstracts

Retrieve all available abstracts of the following 300 articles:
HTML format


 

Single Articles

  1. GRIVAS P, Koshkin VS, Chu X, Cole S, et al
    PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant Chemotherapy.
    Eur Urol Oncol. 2023 Dec 27:S2588-9311(23)00288.
    PubMed    
    Abstract available

  2. WANG T, Ding G, Wang X, Cui Y, et al
    Expression of EPB41L2 in Cancer-Associated Fibroblasts: Prognostic Implications for Bladder Cancer and Response to Immunotherapy.
    Arch Med Res. 2023;55:102927.
    PubMed    
    Abstract available

  3. LIU P, Cai L, Yu R, Cao Q, et al
    Significance of Normalized Apparent Diffusion Coefficient in the Vesical Imaging-Reporting and Data System for Diagnosing Muscle-Invasive Bladder Cancer.
    J Magn Reson Imaging. 2023 Dec 28. doi: 10.1002/jmri.29208.
    PubMed    
    Abstract available

  4. ELBAEK SK, Andreasen TG, Taber A, Young-Halvorsen K, et al
    Immune Contexture Changes Following Blue Light Cystoscopy with Hexaminolevulinate in Bladder Cancer.
    Eur Urol Open Sci. 2023;58:37-46.
    PubMed    
    Abstract available


  5. Retraction: Kinesin family member 3A stimulates cell proliferation, migration, and invasion of bladder cancer cells in vitro and in vivo.
    FEBS Open Bio. 2023 Dec 27. doi: 10.1002/2211-5463.13756.
    PubMed    
    Abstract available

  6. XIA Y, Liu X, Ma B, Huang T, et al
    Development and validation of a novel nomogram model for predicting the survival of patients with T2-4a, N0-x, M0 bladder cancer: a retrospective cohort study.
    Am J Clin Exp Urol. 2023;11:500-515.
    PubMed    
    Abstract available

  7. SHATKOVSKAYA O, Kaidarova D, Ongarbayev B, Sagi M, et al
    Five-year overall survival of patients with advanced bladder cancer in Kazakhstan: OSURK registry study.
    Am J Clin Exp Urol. 2023;11:542-548.
    PubMed    
    Abstract available

  8. SHIN JH, An JH, Park SM, Lim GH, et al
    Changes in Urinary Exosomal Nuclear Matrix Protein-22 in Dogs With Urothelial Carcinoma: A Pilot Study.
    In Vivo. 2024;38:190-195.
    PubMed    
    Abstract available

  9. CHEN YH, Chen CT, Wu HP
    Effect of Danshen for improving clinical outcomes in patients with bladder cancer: a retrospective, population-based study.
    Front Pharmacol. 2023;14:1260683.
    PubMed    
    Abstract available

  10. ZHANG N, Qu X, Zhang X, Sun X, et al
    Immunotherapy-Induced Hypophysitis Following Treatment With Tislelizumab in an Elderly Patient With Bladder Cancer and Prostate Cancer: A Case Report.
    Cureus. 2023;15:e51015.
    PubMed    
    Abstract available

  11. NAM W, Chae HK, Jung Y, Kang H, et al
    HER2 positivity predicts BCG unresponsiveness and adaptive immune cell exhaustion in EORTC risk-stratified cohort of bladder cancer.
    Front Immunol. 2023;14:1301510.
    PubMed    
    Abstract available

  12. PFISTER C, Gravis G, Flechon A, Chevreau C, et al
    Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
    Lancet Oncol. 2023 Dec 21:S1470-2045(23)00587.
    PubMed    
    Abstract available

  13. MERTENS LS, van der Heijden MS
    Accelerating neoadjuvant chemotherapy for muscle-invasive bladder cancer.
    Lancet Oncol. 2023 Dec 21:S1470-2045(23)00626.
    PubMed    


  14. KALWA PL, Walz S, Granai M, Fend F, et al
    Differentiation of bladder cancer with water flow elastography (WaFE).
    J Mech Behav Biomed Mater. 2023;150:106319.
    PubMed    
    Abstract available

  15. ZAMEER U, Shaikh W
    A new era for bladder cancer: Enfortumab vedotin and pembrolizumab milestone approval.
    Tumori. 2023 Dec 23:3008916231221508. doi: 10.1177/03008916231221508.
    PubMed    
    Abstract available

  16. WANG X, Liu M, Stevinson C, Dai YB, et al
    Effect of a Single Light-intensity Walking Session on Sleep Quality of Patients with Bladder Cancer: A Randomized Cross-Over Study.
    Semin Oncol Nurs. 2023 Dec 22:151571. doi: 10.1016/j.soncn.2023.151571.
    PubMed    
    Abstract available

  17. LOZAR T, Wang W, Gavrielatou N, Christensen L, et al
    Emerging Prognostic and Predictive Significance of Stress Keratin 17 in HPV-Associated and Non HPV-Associated Human Cancers: A Scoping Review.
    Viruses. 2023;15:2320.
    PubMed    
    Abstract available

  18. MARCHENKO IV, Trushina DB
    Local Drug Delivery in Bladder Cancer: Advances of Nano/Micro/Macro-Scale Drug Delivery Systems.
    Pharmaceutics. 2023;15:2724.
    PubMed    
    Abstract available

  19. SILVA A, Felix A, Cerqueira M, Goncalves CS, et al
    Effects of Lactate Transport Inhibition by AZD3965 in Muscle-Invasive Urothelial Bladder Cancer.
    Pharmaceutics. 2023;15:2688.
    PubMed    
    Abstract available

  20. KUAN FC, Li JM, Huang YC, Chang SF, et al
    Therapeutic Potential of Regorafenib in Cisplatin-Resistant Bladder Cancer with High Epithelial-Mesenchymal Transition and Stemness Properties.
    Int J Mol Sci. 2023;24:17610.
    PubMed    
    Abstract available

  21. VIEIRA DE SOUSA T, Guedes de Pinho P, Pinto J
    Metabolomic Signatures of Treatment Response in Bladder Cancer.
    Int J Mol Sci. 2023;24:17543.
    PubMed    
    Abstract available

  22. ALONSO JCC, de Souza BR, Reis IB, de Arruda Camargo GC, et al
    OncoTherad((R)) (MRB-CFI-1) Nanoimmunotherapy: A Promising Strategy to Treat Bacillus Calmette-Guerin-Unresponsive Non-Muscle-Invasive Bladder Cancer: Crosstalk among T-Cell CX3CR1, Immune Checkpoints, and the Toll-Like Receptor 4 Signaling Pathway.
    Int J Mol Sci. 2023;24:17535.
    PubMed    
    Abstract available

  23. RUSSO P, Marino F, Rossi F, Bizzarri FP, et al
    Is Systemic Immune-Inflammation Index a Real Non-Invasive Biomarker to Predict Oncological Outcomes in Patients Eligible for Radical Cystectomy?
    Medicina (Kaunas). 2023;59:2063.
    PubMed    
    Abstract available

  24. MASTROIANNI R, Iannuzzi A, Ragusa A, Tuderti G, et al
    Health Related Quality of Life in Patients with Bladder Cancer Receiving a Radical Cystectomy.
    Cancers (Basel). 2023;15:5830.
    PubMed    
    Abstract available

  25. SCHEIPNER L, Zurl H, Altziebler JV, Pichler GP, et al
    Charlson-Deyo Comorbidity Index as a Novel Predictor for Recurrence in Non-Muscle-Invasive Bladder Cancer.
    Cancers (Basel). 2023;15:5770.
    PubMed    
    Abstract available

  26. YE Y, Luo Z, Qiu Z, Cao K, et al
    Radiomics Prediction of Muscle Invasion in Bladder Cancer Using Semi-Automatic Lesion Segmentation of MRI Compared with Manual Segmentation.
    Bioengineering (Basel). 2023;10:1355.
    PubMed    
    Abstract available

  27. LONE Z, Benidir T, Wood A, Campbell RA, et al
    Oncologic outcomes of intravesical therapy in the management of nonmuscle invasive bladder cancer with variant histology.
    Urol Oncol. 2023 Dec 21:S1078-1439(23)00471.
    PubMed    
    Abstract available

  28. HOUSSIAU H, Pairet G, Dano H, Seront E, et al
    The Role of c-MET as a Biomarker in Patients with Bladder Cancer Treated with Radical Chemo-Radiotherapy.
    Curr Oncol. 2023;30:10550-10555.
    PubMed    
    Abstract available

  29. RAN S, Yang J, Hu J, Fang L, et al
    Identifying Optimal Candidates for Trimodality Therapy among Nonmetastatic Muscle-Invasive Bladder Cancer Patients.
    Curr Oncol. 2023;30:10166-10178.
    PubMed    
    Abstract available

  30. BISWAS A, Sahoo S, Riedlinger GM, Ghodoussipour S, et al
    Transcriptional state dynamics lead to heterogeneity and adaptive tumor evolution in urothelial bladder carcinoma.
    Commun Biol. 2023;6:1292.
    PubMed    
    Abstract available

  31. HEIDRICH V, Mariotti ACH, Inoue LT, Coser EM, et al
    The bladder microbiota is not significantly altered by intravesical BCG therapy.
    Urol Oncol. 2024;42:22.
    PubMed    
    Abstract available

  32. YE J, Chen Z, Pan Y, Liao X, et al
    The Prognostic Value of Preoperative Naples Prognostic Score in Upper Tract Urothelial Carcinoma Patients after Radical Nephroureterectomy.
    Nutr Cancer. 2024;76:80-88.
    PubMed    
    Abstract available

  33. MCELREE IM, Belzer A, Mott SL, Packiam VT, et al
    Sequential endoluminal gemcitabine and docetaxel for the treatment of clinically non-invasive high-grade upper tract urothelial carcinoma.
    Urol Oncol. 2024;42:20.
    PubMed    
    Abstract available

  34. ARON M, Chandrashekar DS, Canete-Portillo S, Brimo F, et al
    Nested and Large Nested Subtypes of Urothelial Carcinoma of the Upper Urinary Tract: A Multi-institutional Study.
    Mod Pathol. 2023;36:100333.
    PubMed    
    Abstract available

  35. JACOB JM, Woldu SL, Linehan J, Labbate C, et al
    First analysis of the safety and efficacy of UGN-101 in the treatment of ureteral tumors.
    Urol Oncol. 2024;42:20.
    PubMed    
    Abstract available

  36. LIU C, Cong Y, Chen L, Lv F, et al
    Hsa_circ_0001583 fuels bladder cancer metastasis by promoting staphylococcal nuclease and tudor domain containing 1-mediated MicroRNA decay.
    Neoplasia. 2024;47:100963.
    PubMed    
    Abstract available

  37. POMPA IR, Qi D, Ghosh A, Goldberg SI, et al
    Longitudinal Analysis of Bladder Cancer-Specific Mortality Trends in the United States.
    Bladder Cancer. 2023;9:345-353.
    PubMed    
    Abstract available

  38. WANG EY, Armas-Phan M, Meng MV, Loeb S, et al
    Wake-Up Call to Address Sleep Health in Non-Muscle Invasive Bladder Cancer: Underappreciated Contributor to Poor Quality of Life.
    Bladder Cancer. 2023;9:323-326.
    PubMed    
    Abstract available

  39. YONESE I, Numao N, Inamura K, Yoneoka Y, et al
    A case of neoadjuvant chemotherapy-resistant muscle-invasive bladder cancer that markedly responded to pembrolizumab before conversion radical cystectomy.
    IJU Case Rep. 2023;7:64-67.
    PubMed    
    Abstract available

  40. AOKI T, Furuya R, Fukasawa M, Nozawa M, et al
    Bladder cancer with urinary diversion by a sigmoid colon conduit after transverse colon stoma.
    IJU Case Rep. 2023;7:46-49.
    PubMed    
    Abstract available

  41. GHOSH I, Dey Ghosh R, Mukhopadhyay S
    Identification of genes associated with gall bladder cell carcinogenesis: Implications in targeted therapy of gall bladder cancer.
    World J Gastrointest Oncol. 2023;15:2053-2063.
    PubMed    
    Abstract available

  42. MA J, Hu J, Zhao L, Wu Z, et al
    Identification of clinical prognostic factors and analysis of ferroptosis-related gene signatures in the bladder cancer immune microenvironment.
    BMC Urol. 2024;24:6.
    PubMed    
    Abstract available

  43. CHEN X, Feng X, Chen Y, Huang F, et al
    CT findings and clinical characteristics in distinguishing renal urothelial carcinoma mimicking renal cell carcinoma from clear cell renal cell carcinoma.
    BMC Urol. 2024;24:4.
    PubMed    
    Abstract available

  44. CHATTERJEE D, Mou SI, Sultana T, Hosen MI, et al
    Identification and validation of prognostic signature genes of bladder cancer by integrating methylation and transcriptomic analysis.
    Sci Rep. 2024;14:368.
    PubMed    
    Abstract available

  45. NUNES SP, Morales L, Rubio C, Munera-Maravilla E, et al
    Modulation of tumor microenvironment by targeting histone acetylation in bladder cancer.
    Cell Death Discov. 2024;10:1.
    PubMed    
    Abstract available

  46. HUANG G, Xiong H, Li S, Zhu Y, et al
    The efficacy of immune checkpoint inhibitors therapy versus chemotherapy in the treatment of advanced and metastatic urothelial carcinoma: a meta-analysis.
    J Cancer Res Clin Oncol. 2024;150:5.
    PubMed    
    Abstract available

  47. SHAH D, Young K
    Exploring Pembrolizumab-Induced Myocarditis, Myositis, and Myasthenia Gravis: A Comprehensive Literature Review and Case Presentation on Bladder Cancer.
    Cureus. 2023;15:e49867.
    PubMed    
    Abstract available

  48. PENG T, Xiong K, He Z, Cheng S, et al
    Acyl-coenzyme A: cholesterol acyltransferase inhibitor avasimibe suppresses tumorigenesis and induces G1-phase cell-cycle arrest by activating PPARgamma signaling pathway in bladder cancer.
    J Cancer. 2024;15:370-382.
    PubMed    
    Abstract available

  49. ZHAO Y, Lin S, Zeng W, Lin X, et al
    JS-K activates G2/M checkpoints through the DNA damage response and induces autophagy via CAMKKbeta/AMPKalpha/mTOR pathway in bladder cancer cells.
    J Cancer. 2024;15:343-355.
    PubMed    
    Abstract available

  50. TAN M, Pan Q, Yu C, Zhai X, et al
    PIGT promotes cell growth, glycolysis, and metastasis in bladder cancer by modulating GLUT1 glycosylation and membrane trafficking.
    J Transl Med. 2024;22:5.
    PubMed    
    Abstract available

  51. GAO HY, Liu GJ, Qiu YR
    Siglec-15 regulates cell proliferation, migration and invasion in bladder cancer.
    Asian J Surg. 2024 Jan 1:S1015-9584(23)02105.
    PubMed    


  52. UM PK, Praharaj M, Lombardo KA, Yoshida T, et al
    Improved bladder cancer antitumor efficacy with a recombinant BCG that releases a STING agonist.
    bioRxiv. 2023 Dec 15:2023.12.15.571740. doi: 10.1101/2023.12.15.571740.
    PubMed    
    Abstract available

  53. PALMBOS P, Wang Y, Jerome N, Kelleher A, et al
    TRIM29 promotes bladder cancer invasion by regulating the intermediate filament network and focal adhesion.
    Res Sq. 2023 Dec 12:rs.3.rs-3697712. doi: 10.21203/rs.3.rs-3697712.
    PubMed    
    Abstract available

  54. FURUYA H, Sakatani T, Tanaka S, Murakami K, et al
    Bladder cancer risk stratification with the Oncuria 10-plex bead-based urinalysis assay using three different Luminex xMAP instrumentation platforms.
    J Transl Med. 2024;22:8.
    PubMed    
    Abstract available

  55. LU M, Li Y, Hu D, Yu J, et al
    Hepatoid adenocarcinoma in ureter with next-generation sequencing: A case report and literature review.
    BMC Med Genomics. 2024;17:7.
    PubMed    
    Abstract available

  56. WEI W, Liu K, Huang X, Tian S, et al
    EIF4A3-mediated biogenesis of circSTX6 promotes bladder cancer metastasis and cisplatin resistance.
    J Exp Clin Cancer Res. 2024;43:2.
    PubMed    
    Abstract available

  57. FENG Y, Huang Z, Song L, Li N, et al
    PDE3B regulates KRT6B and increases the sensitivity of bladder cancer cells to copper ionophores.
    Naunyn Schmiedebergs Arch Pharmacol. 2024 Jan 2. doi: 10.1007/s00210-023-02928.
    PubMed    
    Abstract available

  58. LIU J, Gao Y, Song C, Liao W, et al
    Immunotherapeutic prospects and progress in bladder cancer.
    J Cell Mol Med. 2024 Jan 2. doi: 10.1111/jcmm.18101.
    PubMed    
    Abstract available

  59. WEI Y, Zhuang Y, Zhang Y, Luo L, et al
    Role of heat shock protein 70 in silibinin-induced apoptosis in bladder cancer.
    J Cancer. 2024;15:79-89.
    PubMed    
    Abstract available

  60. TANG D, Yan Y, Li Y, Li Y, et al
    Targeting DAD1 gene with CRISPR-Cas9 system transmucosally delivered by fluorinated polylysine nanoparticles for bladder cancer intravesical gene therapy.
    Theranostics. 2024;14:203-219.
    PubMed    
    Abstract available

  61. PYUN JH, Son NH, Ko YH, Kim SW, et al
    The Long-Term Impact of 5-alpha Reductase Inhibitors on the Development of Bladder Cancer and the Need for Radical Cystectomy: A Nationwide Observational Study.
    World J Mens Health. 2024 Jan 2. doi: 10.5534/wjmh.230137.
    PubMed    
    Abstract available

  62. YAO Z, Yang H, Liu X, Jiang M, et al
    Preliminary study on the role of the CSMD2 gene in bladder cancer.
    Heliyon. 2023;10:e22593.
    PubMed    
    Abstract available

  63. LIM KY, Chu K, Rajarubendra N, Huang J, et al
    Patterns of chemotherapy use in muscle-invasive bladder cancer in a tertiary centre.
    Bladder (San Franc). 2023;10:e21200013.
    PubMed    
    Abstract available

  64. LI J, Liu J, Wang H, Ma J, et al
    Single-cell analyses EMP1 as a marker of the ratio of M1/M2 macrophages is associated with EMT, immune infiltration, and prognosis in bladder cancer.
    Bladder (San Franc). 2023;10:e21200011.
    PubMed    
    Abstract available

  65. FERNANDES CN, Vale L, Sousa JV, Lopes TA, et al
    Surgeon experience in second-look transurethral resection of bladder cancer - a prospective study.
    Actas Urol Esp (Engl Ed). 2023 Dec 29:S2173-5786(23)00143.
    PubMed    
    Abstract available

  66. KITAMURA K, Nonami T, Muto S, Horie S, et al
    Small cell bladder carcinoma treated with nivolumab as adjuvant maintenance therapy.
    BMJ Case Rep. 2023;16:e257402.
    PubMed    
    Abstract available

  67. OMER ME, Mustafa M, Ali N, Abd Rahman NH, et al
    Non-Mixture Cure Model Estimation in Bladder Cancer Patients: A Novel Approach with Exponentiated Weibull Exponential Distribution.
    Asian Pac J Cancer Prev. 2023;24:4167-4177.
    PubMed    
    Abstract available

  68. GAO Z, Qi N, Qin X, Li Z, et al
    The addition of tislelizumab to gemcitabine and cisplatin chemotherapy increases thrombocytopenia in patients with urothelial carcinoma: A single-center study based on propensity score matching.
    Cancer Med. 2023;12:22071-22080.
    PubMed    
    Abstract available

  69. ZHANG C, Huang MN, Shan JQ, Hu ZJ, et al
    Pemigatinib, a selective FGFR inhibitor overcomes ABCB1-mediated multidrug resistance in cancer cells.
    Biochem Biophys Res Commun. 2024;691:149314.
    PubMed    
    Abstract available

  70. NAKAMOTO T, Yoshida T, Katayama S, Ohe C, et al
    ASO Visual Abstract: Development and Validation of a Preoperative Nomogram for Endoscopic Management Decision Making in Upper Urinary Tract Urothelial Carcinoma.
    Ann Surg Oncol. 2024;31:1416-1417.
    PubMed    


  71. SHI K, Zhou J, Li M, Yan W, et al
    Pan-cancer analysis of PLAU indicates its potential prognostic value and correlation with neutrophil infiltration in BLCA.
    Biochim Biophys Acta Mol Basis Dis. 2024;1870:166965.
    PubMed    
    Abstract available

  72. CHEN J, Tang Y, Liu H, Sun G, et al
    The mutational pattern of homologous recombination repair genes in urothelial carcinoma and its correlation with immunotherapeutic response.
    Cancer Med. 2023;12:22370-22380.
    PubMed    
    Abstract available

  73. GRIVAS P, Grande E, Davis ID, Moon HH, et al
    Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice.
    ESMO Open. 2023;8:102050.
    PubMed    
    Abstract available

  74. NAKAMOTO T, Yoshida T
    ASO Author Reflections: Endoscopic Management of Upper Urinary Tract Urothelial Carcinoma: A Preoperative Nomogram.
    Ann Surg Oncol. 2024;31:1412-1413.
    PubMed    


  75. NAKAMOTO T, Yoshida T, Katayama S, Ohe C, et al
    Development and Validation of a Preoperative Nomogram for Endoscopic Management Decision Making in Upper Urinary Tract Urothelial Carcinoma.
    Ann Surg Oncol. 2024;31:1393-1401.
    PubMed    
    Abstract available

  76. MORIZANE S, Nakane K, Tanaka T, Zennami K, et al
    Comparison of perioperative outcomes and complications between intracorporeal, extracorporeal, and hybrid ileal conduit urinary diversion during robot-assisted radical cystectomy: a comparative propensity score-matched analysis from nationwide multi-i
    Int J Clin Oncol. 2024;29:64-71.
    PubMed    
    Abstract available

  77. KAGAWA H, Urabe F, Kiuchi Y, Katsumi K, et al
    Real-world outcomes of adjuvant immunotherapy candidates with upper tract urothelial carcinoma: results of a multicenter cohort study.
    Int J Clin Oncol. 2024;29:55-63.
    PubMed    
    Abstract available

  78. DING M, Liu Z, Li W, Wang T, et al
    Robot-assisted partial cystectomy for the treatment of inflammatory myofibroblastic tumor of urinary bladder: A case report.
    Asian J Surg. 2024;47:681-682.
    PubMed    


  79. VANDENBUSSCHE CJ, Heaney CD, Kates M, Hooks JJ, et al
    Urinary IL-6 and IL-8 as predictive markers in bladder urothelial carcinoma: A pilot study.
    Cancer Cytopathol. 2024;132:50-59.
    PubMed    
    Abstract available

  80. ZHOU H, Pan Y, Xu M, Wang S, et al
    Intracavitary Chemotherapy after kidney-Sparing Therapy for Upper Tract Urothelial Carcinoma: A Meta-Analysis.
    Urol J. 2023;20:369-378.
    PubMed    
    Abstract available

  81. LUO Z, Jiao B, Zhao H, Huang T, et al
    Comparison of different prediction tools for the risk of intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinoma: a propensity-matched analysis.
    Clin Transl Oncol. 2024;26:136-146.
    PubMed    
    Abstract available

  82. KAO CC, Lai CR, Lin YH, Chen TM, et al
    GW4064 inhibits migration and invasion through cathepsin B and MMP2 downregulation in human bladder cancer.
    Chem Biol Interact. 2024 Jan 10:110869. doi: 10.1016/j.cbi.2024.110869.
    PubMed    
    Abstract available

  83. WANG H, Liu J, Tang R, Hu J, et al
    Deciphering the significance of anoikis in bladder cancer and systematic analysis of S100A7 as a potential therapeutic target.
    Eur J Med Res. 2024;29:52.
    PubMed    
    Abstract available

  84. YUAN H, Mao X, Yan Y, Huang R, et al
    Single-cell sequencing reveals the heterogeneity of B cells and tertiary lymphoid structures in muscle-invasive bladder cancer.
    J Transl Med. 2024;22:48.
    PubMed    
    Abstract available

  85. WANG Y, Tang Y, Liu Z, Tan X, et al
    Identification of an inflammation-related risk signature for prognosis and immunotherapeutic response prediction in bladder cancer.
    Sci Rep. 2024;14:1216.
    PubMed    
    Abstract available

  86. TAKEUCHI H, Nakata W, Matsuse M, Tsujimura G, et al
    Preoperative Immunonutrition Significantly Reduced Surgical Site Infection After Urinary Diversion for Invasive Bladder Cancer: A Retrospective Cohort Study.
    Clin Genitourin Cancer. 2023 Dec 13:S1558-7673(23)00269.
    PubMed    
    Abstract available

  87. XIA Y, Ma BB, Liu X, Xu DF, et al
    Explore the prognostic influence of the treatment sequence of TURBT-chemotherapy combination for patients with localized muscle-invasive bladder cancer.
    Asian J Surg. 2024 Jan 11:S1015-9584(24)00014.
    PubMed    


  88. GAN Z, Abudurexiti A, Hu X, Chen W, et al
    E2F3/5/8 serve as potential prognostic biomarkers and new therapeutic direction for human bladder cancer.
    Medicine (Baltimore). 2024;103:e35722.
    PubMed    
    Abstract available

  89. YANG R, Rac G, Felice MD, Pahouja G, et al
    Robotic versus open radical cystectomy for bladder cancer: evaluation of complications, survival, and opioid prescribing patterns.
    J Robot Surg. 2024;18:10.
    PubMed    
    Abstract available

  90. HUANG Q, Li Z, Liu C
    Prognostic Value of Fatty Acid Metabolism-related Genes in Patients with Bladder Cancer.
    Recent Pat Anticancer Drug Discov. 2024;19:328-341.
    PubMed    
    Abstract available

  91. A BUENO AP, Clark O, Turnure M, Moreira ES, et al
    Treatment patterns in metastatic bladder cancer in Japan: results of the CancerMPact((R)) survey 2020.
    Future Oncol. 2024 Jan 12. doi: 10.2217/fon-2023-0197.
    PubMed    
    Abstract available

  92. ZHANG W, Yu L, Chang Z, Xiong H, et al
    BCG immunotherapy promotes tumor-derived T-cell activation through the FLT3/FLT3LG pathway in bladder cancer.
    J Cancer. 2024;15:623-631.
    PubMed    
    Abstract available

  93. DU W, Guo K, Wang P, Zhong J, et al
    HSPB8 Facilitates the Oncogenesis and Advancement of Bladder Cancer via Activation of HSP27.
    J Cancer. 2024;15:645-658.
    PubMed    
    Abstract available

  94. ZHANG P, Yang Q, Chen X, Chen X, et al
    CENPW knockdown inhibits progression of bladder cancer through inducing cell cycle arrest and apoptosis.
    J Cancer. 2024;15:858-870.
    PubMed    
    Abstract available

  95. RICHTERS A, Robbrecht DGJ, Meijer RP, van der Heijden AG, et al
    Treatment Patterns and Use of Immune Checkpoint Inhibitors Among Patients with Metastatic Bladder Cancer in a Dutch Nationwide Cohort.
    Eur Urol Open Sci. 2023;59:50-54.
    PubMed    
    Abstract available

  96. YI J, Ma X, Ying Y, Liu Z, et al
    N6-methyladenosine-modified CircPSMA7 enhances bladder cancer malignancy through the mir-128-3p/MAPK1 axis.
    Cancer Lett. 2024 Jan 9:216613. doi: 10.1016/j.canlet.2024.216613.
    PubMed    
    Abstract available

  97. ZANG PD, Angeles A, Dorff TB, Pal SK, et al
    Immuno-Oncology Advances in Genitourinary Cancers.
    Am Soc Clin Oncol Educ Book. 2024;44:e430428.
    PubMed    
    Abstract available

  98. ZHOU H, Cui X, Zhu L, Xu Z, et al
    circPVT1 Inhibits the Proliferation and Aids in Prediction of the Prognosis of Bladder Cancer.
    Pharmgenomics Pers Med. 2024;17:1-11.
    PubMed    
    Abstract available

  99. TUO Z, Feng D, Jiang Z, Bi L, et al
    Unveiling clinical significance and tumor immune landscape of CXCL12 in bladder cancer: Insights from multiple omics analysis.
    Chin J Cancer Res. 2023;35:686-701.
    PubMed    
    Abstract available

  100. REYNOLDS T, Riddick G, Meyers G, Gordon M, et al
    Results Obtained from a Pivotal Validation Trial of a Microsatellite Analysis (MSA) Assay for Bladder Cancer Detection through a Statistical Approach Using a Four-Stage Pipeline of Modern Machine Learning Techniques.
    Int J Mol Sci. 2023;25:472.
    PubMed    
    Abstract available

  101. LASOTA M, Jankowski D, Wisniewska A, Sarna M, et al
    The Potential of Congo Red Supplied Aggregates of Multitargeted Tyrosine Kinase Inhibitor (Sorafenib, BAY-43-9006) in Enhancing Therapeutic Impact on Bladder Cancer.
    Int J Mol Sci. 2023;25:269.
    PubMed    
    Abstract available

  102. REYNOLDS T, Bertsche K, Moon D, Moon C, et al
    Qualification of the Microsatellite Instability Analysis (MSA) for Bladder Cancer Detection: The Technical Challenges of Concordance Analysis.
    Int J Mol Sci. 2023;25:209.
    PubMed    
    Abstract available

  103. LEE SY, Lee YH, Kim TM, Ha US, et al
    Longitudinal Transcription Profiling of Bladder Cancers Dictate the Response to BCG Treatment and Disease Progression.
    Int J Mol Sci. 2023;25:144.
    PubMed    
    Abstract available

  104. QURESHI TA, Chen X, Xie Y, Murakami K, et al
    MRI/RNA-Seq-Based Radiogenomics and Artificial Intelligence for More Accurate Staging of Muscle-Invasive Bladder Cancer.
    Int J Mol Sci. 2023;25:88.
    PubMed    
    Abstract available

  105. LAUFER M, Perelman M, Segal G, Sarfaty M, et al
    Low Alanine Aminotransferase as a Marker for Sarcopenia and Frailty, Is Associated with Decreased Survival of Bladder Cancer Patients and Survivors-A Retrospective Data Analysis of 3075 Patients.
    Cancers (Basel). 2023;16:174.
    PubMed    
    Abstract available

  106. SUN Y, Liu X, Tong H, Yin H, et al
    SIRT1 Promotes Cisplatin Resistance in Bladder Cancer via Beclin1 Deacetylation-Mediated Autophagy.
    Cancers (Basel). 2023;16:125.
    PubMed    
    Abstract available

  107. LV Y, Liu Z, Deng L, Xia S, et al
    Hesperetin promotes bladder cancer cells death via the PI3K/AKT pathway by network pharmacology and molecular docking.
    Sci Rep. 2024;14:1009.
    PubMed    
    Abstract available

  108. MANKAN AK, Mankan N, de Las Heras B, Ramkissoon SH, et al
    Bladder Cancer, Loss of Y Chromosome, and New Opportunities for Immunotherapy.
    Adv Ther. 2024 Jan 10. doi: 10.1007/s12325-023-02758.
    PubMed    
    Abstract available

  109. PYRGIDIS N, Volz Y, Ebner B, Kazmierczak PM, et al
    The effect of hospital caseload on perioperative mortality, morbidity and costs in bladder cancer patients undergoing radical cystectomy: results of the German nationwide inpatient data.
    World J Urol. 2024;42:19.
    PubMed    
    Abstract available

  110. CHEN CY, Chang CH, Yang CR, Hsieh KL, et al
    Prognostic factors of intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinoma.
    World J Urol. 2024;42:22.
    PubMed    
    Abstract available

  111. KIM K, Byun YJ, Zheng CM, Moon S, et al
    COL6A1 expression as a potential prognostic biomarker for risk stratification of T1 high grade bladder cancer: Unveiling the aggressive nature of a distinct non-muscle invasive subtype.
    Investig Clin Urol. 2024;65:94-103.
    PubMed    
    Abstract available

  112. LI X
    Editorial for "Significance of Normalized Apparent Diffusion Coefficient in the Vesical Imaging-Reporting and Data System for Diagnosing Muscle-Invasive Bladder Cancer".
    J Magn Reson Imaging. 2024 Jan 10. doi: 10.1002/jmri.29233.
    PubMed    


  113. WU Z, Wang D, Zhang Y, Zhang Z, et al
    SPP1 mRNA determination based on molecular beacon for the recurrence prognosis of bladder cancer.
    Transl Androl Urol. 2023;12:1834-1844.
    PubMed    
    Abstract available

  114. SHEN J, Chen C, Chen Z, Gong P, et al
    CCL5 promotes the proliferation and metastasis of bladder cancer via the JAK2/STAT3 signaling pathway.
    Transl Androl Urol. 2023;12:1845-1858.
    PubMed    
    Abstract available

  115. ZHU MR, Hong HX, Cheng JR, Tang J, et al
    Risk Factors Analysis and Pathogen Distribution of Urinary Tract Infection in Patients Undergoing Cutaneous Ureterostomy After Radical Cystectomy for Bladder Cancer.
    Biol Res Nurs. 2024 Jan 9:10998004241226948. doi: 10.1177/10998004241226948.
    PubMed    
    Abstract available

  116. BAHLINGER V, Branz A, Strissel PL, Strick R, et al
    Associations of TACSTD2/TROP2 and NECTIN-4/NECTIN-4 with molecular subtypes, PD-L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts.
    Histopathology. 2024 Jan 9. doi: 10.1111/his.15130.
    PubMed    
    Abstract available

  117. CHEN YT, Tu WJ, Ye ZH, Wu CC, et al
    Integration of the cancer cell secretome and transcriptome reveals potential noninvasive diagnostic markers for bladder cancer.
    Proteomics Clin Appl. 2024 Jan 9:e2300033. doi: 10.1002/prca.202300033.
    PubMed    
    Abstract available

  118. GEETHA SD, Chavarria HD, Abdelwahed M, Kataria N, et al
    Granulomatous myocarditis arising from intravesical Bacillus Calmette-Guerin therapy leading to death diagnosed by postmortem examination: a case report.
    J Med Case Rep. 2024;18:12.
    PubMed    
    Abstract available

  119. KRAL M, Kurfurstova D, Hartmann I, Studentova H, et al
    Ewing's sarcoma of the urinary bladder - the urologic and pathologic differential diagnosis and current therapeutic options.
    Klin Onkol. 2023;37:314-319.
    PubMed    
    Abstract available

  120. FURRER MA, Soliman C, Wuethrich PY
    Meticulous initial clinical and pathological staging with standardized long-term follow-up after radical cystectomy is required to validate and improve overall prognostic performance in patients undergoing neoadjuvant chemotherapy for bladder cancer.
    Minerva Urol Nephrol. 2024 Jan 9. doi: 10.23736/S2724-6051.23.05563.
    PubMed    


  121. JINDAL D, Suresh PK, Sreeram S, Holla R, et al
    Immunohistochemical expression of androgen receptors in urothelial carcinoma of urinary bladder. Is it significant? Experience from coastal India.
    Arch Ital Urol Androl. 2023;95:11514.
    PubMed    
    Abstract available

  122. SHI S, Peng G, Luo L, Li D, et al
    Predictive nomograms for risk and prognostic factors in metastatic bladder cancer: a population-based study.
    Transl Cancer Res. 2023;12:3284-3302.
    PubMed    
    Abstract available

  123. SHI H, Tan Z, Duan B, Guo C, et al
    LASS2 enhances chemosensitivity to cisplatin by inhibiting PP2A-mediated beta-catenin dephosphorylation in a subset of stem-like bladder cancer cells.
    BMC Med. 2024;22:19.
    PubMed    
    Abstract available

  124. DAHM P, Maisch P, Lane GI
    Response to letter to the editor on the systematic review "Narrow band imaging versus white light cystoscopy alone for transurethral resection of non-muscle invasive bladder cancer".
    World J Urol. 2024;42:11.
    PubMed    


  125. STEINBERG GD, Shore ND, Redorta JP, Galsky MD, et al
    CREST: phase III study of sasanlimab and Bacillus Calmette-Guerin for patients with Bacillus Calmette-Guerin-naive high-risk non-muscle-invasive bladder cancer.
    Future Oncol. 2024 Jan 8. doi: 10.2217/fon-2023-0271.
    PubMed    
    Abstract available

  126. LV F, Xiong Q, Qi M, Dai C, et al
    Unraveling neoantigen-associated genes in bladder cancer: An in-depth analysis employing 101 machine learning algorithms.
    Environ Toxicol. 2024 Jan 8. doi: 10.1002/tox.24123.
    PubMed    
    Abstract available

  127. CHENG Z, Ye F, Liang Y, Xu C, et al
    Blood lipids, lipid-regulatory medications, and risk of bladder cancer: a Mendelian randomization study.
    Front Nutr. 2023;10:992608.
    PubMed    
    Abstract available

  128. INTERNATIONAL BR
    Retracted: Susceptibility Loci in SLC15A1, UGT1A3, and CWC27 Genes Associated with Bladder Cancer in the Northeast Chinese Population.
    Biomed Res Int. 2023;2023:9767851.
    PubMed    
    Abstract available

  129. OZTURK H, Karapolat I
    Evaluation of response to gemcitabine plus cisplatin-based chemotherapy using positron emission computed tomography for metastatic bladder cancer.
    World J Clin Cases. 2023;11:8447-8457.
    PubMed    
    Abstract available

  130. CHAUHAN SS, Kumar N, Rana F
    Xanthogranulomatous Cholecystitis Mimicking Gall Bladder Cancer: a Diagnostic Dilemma and Review of Literature.
    Indian J Surg Oncol. 2023;14:796-799.
    PubMed    
    Abstract available

  131. TASHIRO Y, Teishima J, Sakata H, Mita Y, et al
    Ureteral obstruction following transurethral resection of bladder cancer within the Hutch's diverticulum.
    Int Cancer Conf J. 2023;13:45-48.
    PubMed    
    Abstract available

  132. SU WT, Chen JY, Sun JB, Huang QI, et al
    Fatty acid metabolism-related molecular subtypes and a novel model for predicting prognosis in bladder cancer patients.
    J Biosci. 2024;49:11.
    PubMed    
    Abstract available

  133. DEMA V, Croitor A, Floruncut A, Dema S, et al
    Incidental carcinoma of the prostate in cystoprostatectomy specimens - is it always a toothless lion?
    Rom J Morphol Embryol. 2023;64:501-507.
    PubMed    
    Abstract available

  134. LI R, Nocera L, Rose KM, Raggi D, et al
    Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer.
    Eur Urol Oncol. 2024 Jan 5:S2588-9311(23)00296-1. doi: 10.1016/j.euo.2023.
    PubMed    
    Abstract available

  135. YANG Y, Yang B, Xu J, Liu J, et al
    Prostate cancer was detected after radical resection of bladder cancer.
    Asian J Surg. 2024 Jan 5:S1015-9584(23)02075.
    PubMed    


  136. FREITAS NR, Vieira PM, Tinoco C, Anacleto S, et al
    Multiple mask and boundary scoring R-CNN with cGAN data augmentation for bladder tumor segmentation in WLC videos.
    Artif Intell Med. 2024;147:102723.
    PubMed    
    Abstract available

  137. LI K, Huang Z, Xie G, Huang B, et al
    Transcriptomic insights into UTUC: role of inflammatory fibrosis and potential for personalized treatment.
    J Transl Med. 2024;22:24.
    PubMed    
    Abstract available

  138. SHUAI Y, Zhang H, Liu C, Wang J, et al
    CLIC3 interacts with NAT10 to inhibit N4-acetylcytidine modification of p21 mRNA and promote bladder cancer progression.
    Cell Death Dis. 2024;15:9.
    PubMed    
    Abstract available

  139. ZHANG F, Yao Z, Zhang B
    Genetically proxied intestinal microbiota and risk of bladder cancer.
    Int J Surg. 2024 Jan 4. doi: 10.1097/JS9.0000000000001019.
    PubMed    


  140. HADJI M, Rashidian H, Marzban M, Rezaianzadeh A, et al
    Unveiling an Association between Waterpipe Smoking and Bladder Cancer Risk: A Multicenter Case-Control Study in Iran.
    Cancer Epidemiol Biomarkers Prev. 2024 Jan 5. doi: 10.1158/1055-9965.EPI-23-0773
    PubMed    
    Abstract available

  141. LIAO RS, Ruan HT, Jang A, Huynh M, et al
    Emerging Insights in Small-Cell Carcinoma of the Genitourinary Tract: From Diagnosis to Novel Therapeutic Horizons.
    Am Soc Clin Oncol Educ Book. 2024;44:e430336.
    PubMed    
    Abstract available

  142. MIAO Z, Li J, Zeng S, Lv Y, et al
    Endoplasmic Reticulum-Targeting AIE Photosensitizers to Boost Immunogenic Cell Death for Immunotherapy of Bladder Carcinoma.
    ACS Appl Mater Interfaces. 2024;16:245-260.
    PubMed    
    Abstract available

  143. GRANDE E, Arranz JA, De Santis M, Bamias A, et al
    Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study.
    Lancet Oncol. 2024;25:29-45.
    PubMed    
    Abstract available

  144. SIEFKER-RADTKE AO, Desai M
    Evolution of front-line immunotherapy for metastatic urothelial cancer.
    Lancet Oncol. 2024;25:2-3.
    PubMed    


  145. BAMIAS A, Davis ID, Galsky MD, Arranz JA, et al
    Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study.
    Lancet Oncol. 2024;25:46-61.
    PubMed    
    Abstract available

  146. MILLER EJ, Galsky MD
    Precision Medicine in Urothelial Carcinoma: Current Markers to Guide Treatment and Promising Future Directions.
    Curr Treat Options Oncol. 2023;24:1870-1888.
    PubMed    
    Abstract available

  147. WANG X, Zeng M, Ju X, Lin A, et al
    Correlation between second and first primary cancer: systematic review and meta-analysis of 9 million cancer patients.
    Br J Surg. 2024;111:znad377.
    PubMed    
    Abstract available

  148. BACHERT SE, Di J, Zhang S, Short HE, et al
    TRPS1 expression in primary and metastatic prostatic adenocarcinoma, muscle invasive bladder urothelial carcinoma, and breast carcinoma: Is TRPS1 truly specific and sensitive for a breast primary?
    Hum Pathol. 2024;143:42-49.
    PubMed    
    Abstract available

  149. RAN P, Zhou W, Zhang X, Lv J, et al
    FDG PET/CT in a Case of Primary Lymphoma of the Ureter.
    Clin Nucl Med. 2023 Nov 17. doi: 10.1097/RLU.0000000000004976.
    PubMed    
    Abstract available

  150. LOBO J, Tenace NP, Canete-Portillo S, Carneiro I, et al
    Aberrant expression of GATA3 in metastatic adenocarcinoma of the prostate: an important pitfall.
    Histopathology. 2024;84:507-514.
    PubMed    
    Abstract available

  151. VARMA M, Comperat E, van der Kwast T
    Head-to-head: how many categories for grading urothelial carcinoma?
    Histopathology. 2024;84:421-428.
    PubMed    
    Abstract available

  152. STOCKEM CF, Galsky MD, van der Heijden MS
    Turning up the heat: CTLA4 blockade in urothelial cancer.
    Nat Rev Urol. 2024;21:22-34.
    PubMed    
    Abstract available

  153. LI K, Qi L, Tang G, Xu H, et al
    Epigenetic Regulation in Urothelial Carcinoma.
    Curr Mol Med. 2024;24:85-97.
    PubMed    
    Abstract available

  154. YANG W, Liu J
    Regarding the role of HER2 overexpression on the survival in muscle-invasive bladder cancer.
    Int J Surg. 2024 Jan 18. doi: 10.1097/JS9.0000000000001091.
    PubMed    


  155. ASDEMIR A, Ozgur A
    Molecular mechanism of anticancer effect of heat shock protein 90 inhibitor BIIB021 in human bladder cancer cell line.
    Naunyn Schmiedebergs Arch Pharmacol. 2024.
    PubMed    
    Abstract available

  156. WEI D, Liu Y, Yuan Y, Li Y, et al
    Molecular map of cGAS-STING pathway-related genes in bladder cancer: the perspective toward immune microenvironment and prognosis.
    Aging (Albany NY). 2024;15.
    PubMed    
    Abstract available

  157. JIANG LJ, Guo SB, Zhou ZH, Li ZY, et al
    Snai2-mediated upregulation of NADSYN1 promotes bladder cancer progression by interacting with PHB.
    Clin Transl Med. 2024;14:e1555.
    PubMed    


  158. KOHUT-JACKSON A, Orf J, Barresi D, Davaro F, et al
    Age related trends in the utilization of neoadjuvant chemotherapy for muscle invasive bladder cancer.
    Urol Oncol. 2024 Jan 17:S1078-1439(24)00007.
    PubMed    
    Abstract available

  159. ERMAN A, Kamensek U, Peskar D, Veranic P, et al
    Establishment of Mouse Orthotopic Urinary Bladder Tumor Model and Its Analysis by Light and Electron Microscopy.
    Methods Mol Biol. 2024;2773:33-49.
    PubMed    
    Abstract available

  160. ZUPANCIC D, Romih R
    Urinary Bladder Cancer Induced by N-Butyl-N-(4-Hydroxybutyl)-Nitrosamine.
    Methods Mol Biol. 2024;2773:25-32.
    PubMed    
    Abstract available

  161. OZDEMIR SANCI T, Terzi E, Oz Bedir BE, Gumustas M, et al
    Effect of herniarin on cell viability, cell cycle, and Erk protein levels in different stages of bladder cancer cells.
    Chem Biodivers. 2024 Jan 18:e202301645. doi: 10.1002/cbdv.202301645.
    PubMed    
    Abstract available

  162. LIU Y, Zhang J, Chen H, Zhang W, et al
    Urinary microbiota signatures associated with different types of urinary diversion: a comparative study.
    Front Cell Infect Microbiol. 2024;13:1302870.
    PubMed    
    Abstract available

  163. OZGUN G, Yaras T, Akman B, Ozden-Yilmaz G, et al
    Retinoids and EZH2 inhibitors cooperate to orchestrate anti-oncogenic effects on bladder cancer cells.
    Cancer Gene Ther. 2024 Jan 17. doi: 10.1038/s41417-024-00725.
    PubMed    
    Abstract available

  164. WARRICK J
    Molecular Subtypes of Bladder Cancer: Component Signatures and Potential Value in Clinical Decision-making.
    Adv Anat Pathol. 2024 Jan 18. doi: 10.1097/PAP.0000000000000430.
    PubMed    
    Abstract available

  165. KHOR V, Fahmy O, Lee CKS, Khairul-Asri MG, et al
    Guillain-Barre Syndrome following intravesical Bacillus Calmette-Guerin therapy for bladder cancer: a rare and intriguing case report.
    Cent European J Urol. 2023;76:311-314.
    PubMed    
    Abstract available

  166. DYBOWSKI B
    Local solutions to shorten treatment delays in bladder cancer. Results of a survey among CEJU authors.
    Cent European J Urol. 2023;76:280-282.
    PubMed    


  167. INTERNATIONAL BR
    Retracted: Urinary Angiogenin as a Marker for Bladder Cancer: A Meta-Analysis.
    Biomed Res Int. 2024;2024:9869348.
    PubMed    
    Abstract available

  168. INTERNATIONAL BR
    Retracted: The Use of BT-ESD Technology under General Intravenous Anesthesia in the Treatment of Nonmuscle Invasive Bladder Cancer and the Effect of PI3K/Akt Signaling Pathway on Tumor Recurrence.
    Biomed Res Int. 2024;2024:9815062.
    PubMed    
    Abstract available

  169. WARAICH TA, Khalid SY, Ali A, Kathia UM, et al
    Comparative Outcomes of Radical Cystectomy in Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
    Cureus. 2023;15:e50646.
    PubMed    
    Abstract available

  170. YIN G, Zheng S, Zhang W, Dong X, et al
    Classification of bladder cancer based on immune cell infiltration and construction of a risk prediction model for prognosis.
    Zhejiang Da Xue Xue Bao Yi Xue Ban. 2024.
    PubMed    
    Abstract available

  171. ZHANG HH, Zhang AQ, Peng P, Huang L, et al
    USP5 facilitates bladder cancer progression by stabilizing the c-Jun protein.
    Cancer Cell Int. 2024;24:32.
    PubMed    
    Abstract available

  172. MASONE MC
    Urinoids - a new tool to study bladder cancer.
    Nat Rev Urol. 2024 Jan 16. doi: 10.1038/s41585-024-00853.
    PubMed    


  173. IKARASHI D, Kitano S, Tsuyukubo T, Yamashita M, et al
    Pathological complete response to neoadjuvant chemotherapy may improve antitumor immune response via reduction of regulatory T cells in muscle-invasive bladder cancer.
    Sci Rep. 2024;14:1442.
    PubMed    
    Abstract available

  174. ZHAO L, Li J, Xue Z, Wang J, et al
    Exosomal noncoding RNAs as noninvasive biomarkers in bladder cancer: a diagnostic meta-analysis.
    Clin Transl Oncol. 2024 Jan 16. doi: 10.1007/s12094-023-03374.
    PubMed    
    Abstract available

  175. CHAMIE K, Chang SS, Kramolowsky EV, Gonzalgo ML, et al
    Quality of Life in the Phase 2/3 Trial of N-803 Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer.
    Urol Pract. 2024 Jan 16:101097UPJ0000000000000517.
    PubMed    
    Abstract available

  176. LIEDBERG F, Hagberg O, Aljabery F, Gardmark T, et al
    Diagnostic pathways and treatment strategies in upper tract urothelial carcinoma in Sweden between 2015 and 2021: a population-based survey.
    Scand J Urol. 2024;59:19-25.
    PubMed    
    Abstract available

  177. YANG H, He P, Luo W, Liu S, et al
    circRNA TATA-box binding protein associated factor 15 acts as an oncogene to facilitate bladder cancer progression through targeting miR-502-5p/high mobility group box 3.
    Mol Carcinog. 2024 Jan 16. doi: 10.1002/mc.23677.
    PubMed    
    Abstract available

  178. OKATO A, Utsumi T, Ranieri M, Zheng X, et al
    FGFR inhibition augments anti-PD-1 efficacy in murine FGFR3-mutant bladder cancer by abrogating immunosuppression.
    J Clin Invest. 2024;134:e169241.
    PubMed    
    Abstract available

  179. ESCOBAR GIL T, Borja Montes OF, Sheikh AB
    Unraveling Bacillus Calmette-Guerin (BCG) Therapy Side Effects in Bladder Cancer: A Tale of Triumph Over Treatment Challenges.
    Cureus. 2023;15:e50498.
    PubMed    
    Abstract available

  180. SIMO C, Serra-Casablancas M, Hortelao AC, Di Carlo V, et al
    Urease-powered nanobots for radionuclide bladder cancer therapy.
    Nat Nanotechnol. 2024 Jan 15. doi: 10.1038/s41565-023-01577.
    PubMed    
    Abstract available

  181. AY A, Alkanli N, Cevik G
    Determination of the Roles of Endothelial Nitric Oxide Synthase 4VNTR (4a/b), G894T, T786C Gene Variations in the Bladder Cancer Development.
    Indian J Clin Biochem. 2024;39:92-100.
    PubMed    
    Abstract available

  182. WANG Z, Wang Y, Wang S, Ran Q, et al
    Tislelizumab with gemcitabine and cisplatin as a neoadjuvant regimen for muscle-invasive bladder cancer: case series.
    Ann Med Surg (Lond). 2023;86:245-251.
    PubMed    
    Abstract available

  183. ZEHRA M, Fatima T, Hanif A, Raufi N, et al
    Nadofaragene: a new era of precision medicine for bladder cancer.
    Ann Med Surg (Lond). 2023;86:7-10.
    PubMed    


  184. CHEN JQ, Salas LA, Wiencke JK, Koestler DC, et al
    Matched analysis of detailed peripheral blood and tumor immune microenvironment profiles in bladder cancer.
    Epigenomics. 2024;16:41-56.
    PubMed    
    Abstract available

  185. RUSSO AE, Memon A, Ahmed S
    Bladder Cancer and the Urinary Microbiome-New Insights and Future Directions: A Review.
    Clin Genitourin Cancer. 2024 Jan 9:S1558-7673(23)00281.
    PubMed    
    Abstract available

  186. LI M, Yu J, Ju L, Wang Y, et al
    USP43 stabilizes c-Myc to promote glycolysis and metastasis in bladder cancer.
    Cell Death Dis. 2024;15:44.
    PubMed    
    Abstract available

  187. ZHOU L, Du K, Dai Y, Zeng Y, et al
    Metabolic reprogramming based on RNA sequencing of gemcitabine-resistant cells reveals the FASN gene as a therapeutic for bladder cancer.
    J Transl Med. 2024;22:55.
    PubMed    
    Abstract available

  188. AMIRI Z, Hasani A, Abedini F, Malek M, et al
    Urease-Powered Black TiO(2) Micromotors for Photothermal Therapy of Bladder Cancer.
    ACS Appl Mater Interfaces. 2024 Jan 13. doi: 10.1021/acsami.3c11772.
    PubMed    
    Abstract available

  189. TSIKOPOULOS I, Papadopoulos DI, Anastasiou D, Karatzas A, et al
    Vesical fungal bezoars on post-TURBT scar tissue causing obstruction and mimicking urothelial carcinoma.
    BMJ Case Rep. 2024;17:e257132.
    PubMed    
    Abstract available

  190. ZHUANG Y, Cai Q, Hu X, Huang H, et al
    Elevated serum CA199 levels in patients suffering type 2 diabetes vs. various types of cancer.
    BMC Endocr Disord. 2024;24:9.
    PubMed    
    Abstract available

  191. ZHOU Z, Xiong L, Yao K, Ma H, et al
    Extraperitonealization of the ileal conduit decreases the risk of parastomal hernia: A single-center, randomized clinical trial.
    Cell Rep Med. 2024;5:101343.
    PubMed    
    Abstract available

  192. LAMBERTINI L, Di Maida F, Cadenar A, Nardoni S, et al
    Stentless florence robotic intracorporeal neobladder (FloRIN), a feasibility prospective randomized clinical trial.
    Eur J Surg Oncol. 2024;50:107259.
    PubMed    
    Abstract available

  193. TAJIMA Y, Shibasaki F, Masai H
    Cell fusion upregulates PD-L1 expression for evasion from immunosurveillance.
    Cancer Gene Ther. 2024;31:158-173.
    PubMed    
    Abstract available

  194. HOU J, Huang H, Xie J, Yu W, et al
    KLHDC7B as a novel diagnostic biomarker in urine exosomal mRNA promotes bladder urothelial carcinoma cell proliferation and migration, inhibits apoptosis.
    Mol Carcinog. 2024;63:286-300.
    PubMed    
    Abstract available

  195. CONCI N, Tassinari E, Tateo V, Rosellini M, et al
    How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma?
    Mol Diagn Ther. 2024;28:37-51.
    PubMed    
    Abstract available

  196. MCGREGOR BA, Sonpavde GP, Kwak L, Regan MM, et al
    The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma.
    Ann Oncol. 2024;35:91-97.
    PubMed    
    Abstract available

  197. SIEFKER-RADTKE AO, Matsubara N, Park SH, Huddart RA, et al
    Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.
    Ann Oncol. 2024;35:107-117.
    PubMed    
    Abstract available

  198. XU S, Huang J
    Machine learning algorithms predicting bladder cancer associated with diabetes and hypertension: NHANES 2009 to 2018.
    Medicine (Baltimore). 2024;103:e36587.
    PubMed    
    Abstract available

  199. MARTINS EP, Vieira de Castro J, Fontes R, Monteiro-Reis S, et al
    Relevance of HOTAIR rs920778 and rs12826786 Genetic Variants in Bladder Cancer Risk and Survival.
    Cancers (Basel). 2024;16:434.
    PubMed    
    Abstract available

  200. DESPONDS E, Croci D, Wosika V, Hadadi N, et al
    Immuno-Transcriptomic Profiling of Blood and Tumor Tissue Identifies Gene Signatures Associated with Immunotherapy Response in Metastatic Bladder Cancer.
    Cancers (Basel). 2024;16:433.
    PubMed    
    Abstract available

  201. GARG H, Bhandari M, Dursun F, Liss MA, et al
    A comparative analysis of radical cystectomy with perioperative chemotherapy, chemoradiation therapy, or systemic therapy in patients with clinically advanced node-positive bladder cancer (cN2/N3).
    Front Oncol. 2024;13:1157880.
    PubMed    
    Abstract available

  202. WANG K, Xiao W, Zeng Q
    Curcumin Inhibits Bladder Cancer by Inhibiting Invasion via AKT/MMP14 Pathway.
    Discov Med. 2024;36:71-81.
    PubMed    
    Abstract available

  203. LU J, Hong H, Xiong Z, Zhang Y, et al
    Development and preliminary validation of a PROS scale for Chinese bladder cancer patients with abdominal stoma.
    Sci Rep. 2024;14:2187.
    PubMed    
    Abstract available

  204. SU Z, You L, He Y, Chen J, et al
    Multi-omics reveals the role of ENO1 in bladder cancer and constructs an epithelial-related prognostic model to predict prognosis and efficacy.
    Sci Rep. 2024;14:2189.
    PubMed    
    Abstract available

  205. KOPENHAFER L, Thompson A, Chang J, Sikirica S, et al
    Patient experience and unmet needs in high-risk nonmuscle-invasive bladder cancer: Insights from qualitative interviews and a cross-sectional survey.
    Urol Oncol. 2024 Jan 24:S1078-1439(24)00015.
    PubMed    
    Abstract available

  206. MONTORSI F, Moschini M, Salonia A, Gandaglia G, et al
    Re: Francesco Soria, Matteo Rosazza, Simone Livoti, et al. Repeat Transurethral Resection (TUR) + Bacillus Calmette-Guerin (BCG) Versus Upfront Induction BCG After TUR in High-risk Non-muscle-invasive Bladder Cancer: Feasibility Phase of a Randomized
    Eur Urol Focus. 2024 Jan 24:S2405-4569(24)00005.
    PubMed    


  207. FUKUSHIMA H, Takao S, Furusawa A, Valera Romero V, et al
    Near-infrared photoimmunotherapy targeting Nectin-4 in a preclinical model of bladder cancer.
    Cancer Lett. 2024 Jan 23:216606. doi: 10.1016/j.canlet.2023.216606.
    PubMed    
    Abstract available

  208. WOOLBRIGHT BL, Xuan H, Ahmed I, Rajendran G, et al
    Aging induces changes in cancer formation and microbial content in a murine model of bladder cancer.
    Geroscience. 2024 Jan 25. doi: 10.1007/s11357-024-01064.
    PubMed    
    Abstract available

  209. TRIPATHI S, Bhirud DP, Singh M, Singh V, et al
    Early port site and peritoneal metastasis following robot-assisted radical cystectomy: a rare case report.
    J Cancer Res Clin Oncol. 2024;150:32.
    PubMed    
    Abstract available

  210. SUN R, Zhang M, Yang L, Yang S, et al
    Preoperative CT-based deep learning radiomics model to predict lymph node metastasis and patient prognosis in bladder cancer: a two-center study.
    Insights Imaging. 2024;15:21.
    PubMed    
    Abstract available

  211. YANG J, Ji Z, Gao F, Wu J, et al
    Cigarette smoking combined with genetic variation regulates the m(6) A methylation of CRNKL1 and is associated with bladder cancer risk.
    Environ Toxicol. 2024 Jan 25. doi: 10.1002/tox.24138.
    PubMed    
    Abstract available

  212. TRUONG TH, Nguyen DH, Dinh KN, Thai MS, et al
    Urethral Recurrence After Cystectomy and Orthotopic Bladder Reconstruction: A Rare Case of Recurrent Bladder Cancer After 12 Years and Review of the Literature.
    Clin Med Insights Case Rep. 2024;17:11795476231224188.
    PubMed    
    Abstract available

  213. ENOMOTO T, Okada H, Tomita H, Iinuma K, et al
    Glycocalyx analysis of bladder cancer: three-dimensional images in electron microscopy and vicia villosa lectin as a marker for invasiveness in frozen sections.
    Front Cell Dev Biol. 2024;11:1308879.
    PubMed    
    Abstract available

  214. WEN F, Lin T, Zhang P, Shen Y, et al
    RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2-positive locally advanced muscle-invasive urothelial bladder cancer: a multi-center phase Ib/II study (HOPE-03).
    Front Oncol. 2024;13:1233196.
    PubMed    
    Abstract available

  215. TAK S, Han G, Leem SH, Lee SY, et al
    Prediction of anticancer drug resistance using a 3D microfluidic bladder cancer model combined with convolutional neural network-based image analysis.
    Front Bioeng Biotechnol. 2024;11:1302983.
    PubMed    
    Abstract available

  216. OSSOLINSKI K, Ruman T, Copie V, Tripet BP, et al
    Metabolomic profiling of human bladder tissue extracts.
    Metabolomics. 2024;20:14.
    PubMed    
    Abstract available

  217. SAVIN Z, Mano R, Lazarovich A, Rosenzweig B, et al
    Assessing the Impact of Percutaneous Nephrostomy Presence on Neoadjuvant Treatment Quality in Patients With Muscle Invasive Bladder Cancer.
    Clin Genitourin Cancer. 2024 Jan 6:S1558-7673(24)00004.
    PubMed    
    Abstract available

  218. MCFADDEN J, Tachibana I, Adra N, Collins K, et al
    Impact of variant histology on upstaging and survival in patients with nonmuscle invasive bladder cancer undergoing radical cystectomy.
    Urol Oncol. 2024 Jan 23:S1078-1439(23)00487.
    PubMed    
    Abstract available

  219. RAMOS P, Mateus A, Manso M, Botelho F, et al
    Prognostic impact of variant histology in bladder cancer: Would early and aggressive treatment shift the paradigm?
    Urol Oncol. 2024 Jan 23:S1078-1439(24)00010.
    PubMed    
    Abstract available

  220. WAN S, Li KP, Wang CY, Yang JW, et al
    Immunologic Crosstalk of Endoplasmic Reticulum Stress Signaling in Bladder Cancer.
    Curr Cancer Drug Targets. 2024 Jan 23. doi: 10.2174/0115680096272663231121100515
    PubMed    
    Abstract available

  221. MOHAMED SHARAF R, Essam Eldin-Shibel P, Abd-El-Moeze NA
    Immunohistochemical Expression of Vitamin D Receptor (VDR) in Urinary Bladder Squamous Cell Carcinoma.
    Turk Patoloji Derg. 2024;1.
    PubMed    
    Abstract available

  222. ABOU CHAKRA M, Packiam VT, Duquesne I, Peyromaure M, et al
    Combination intravesical chemotherapy for non-muscle invasive bladder cancer (NMIBC) as first-line or rescue therapy: where do we stand Now?
    Expert Opin Pharmacother. 2024 Jan 24. doi: 10.1080/14656566.2024.2310073.
    PubMed    
    Abstract available

  223. WANG W, Huang G, Lin H, Ren L, et al
    Corrigendum: Label-free LC-MS/MS proteomics analyses reveal CLIC1 as a predictive biomarker for bladder cancer staging and prognosis.
    Front Oncol. 2024;13:1216134.
    PubMed    
    Abstract available

  224. HUANG S, Huang Y, Li C, Liang Y, et al
    Efficacy and safety of neoadjuvant PD-1 inhibitors or PD-L1 inhibitors for muscle invasive bladder cancer: a systematic review and meta-analysis.
    Front Immunol. 2024;14:1332213.
    PubMed    
    Abstract available

  225. ZHAO C, Qi L, Chen M, Liu L, et al
    [Retracted] microRNA?195 inhibits cell proliferation in bladder cancer via inhibition of cell division control protein 42 homolog/signal transducer and activator of transcription?3 signaling.
    Exp Ther Med. 2023;27:78.
    PubMed    
    Abstract available

  226. OUANES Y, Chaker K, Yaich S, Foued D, et al
    Predictive factors of bladder tumor recurrence after radical treatment of upper urinary tract cancer.
    Tunis Med. 2023;101:356-361.
    PubMed    
    Abstract available

  227. CAI Q, Huang Y, Ling J, Kong L, et al
    Radiomics nomogram for predicting disease-free survival after partial resection or radical cystectomy in patients with bladder cancer.
    Br J Radiol. 2024;97:201-209.
    PubMed    
    Abstract available

  228. SU Z, Wei J, Yuan X
    Giant cell-rich solitary fibrous tumour of the urinary bladder: case report of an unusual histological variant and literature review.
    Diagn Pathol. 2024;19:20.
    PubMed    
    Abstract available

  229. WEN F, Lin T, Zhang P, Zeng H, et al
    Bladder sparing by short-course radiotherapy combined with toripalimab in high-risk/extremely high-risk non-muscle invasive bladder cancer (HOPE-04): study protocol for a single-arm, prospective, phase II trial.
    BMJ Open. 2024;14:e076663.
    PubMed    
    Abstract available

  230. CHANG YC, Wu YY, Tsan DL, Yap WK, et al
    Dose-Escalated Radiation Therapy as Primary Treatment for Residual Bladder Cancer After Transurethral Resection.
    Adv Radiat Oncol. 2024;9:101302.
    PubMed    
    Abstract available

  231. ALCANTARA MB, Tang WS, Wang D, Kaniowski D, et al
    Targeting STAT3 in tumor-associated antigen-presenting cells as a strategy for kidney and bladder cancer immunotherapy.
    Front Immunol. 2024;14:1274781.
    PubMed    
    Abstract available

  232. GONG Y, Cheng Y, Zhang J, Bao ML, et al
    Role of Additional MRI-Based Morphologic Measurements on the Performance of VI-RADS for Muscle-Invasive Bladder Cancer.
    J Magn Reson Imaging. 2024 Jan 23. doi: 10.1002/jmri.29184.
    PubMed    
    Abstract available

  233. KOCHERGIN M, Fahmy O, Asimakopoulos A, Theil G, et al
    Photodynamic Therapy: Current Trends and Potential Future Role in the Treatment of Bladder Cancer.
    Int J Mol Sci. 2024;25:960.
    PubMed    
    Abstract available

  234. SHAN KS, Dalal S, Thaw Dar NN, McLish O, et al
    Molecular Targeting of the Fibroblast Growth Factor Receptor Pathway across Various Cancers.
    Int J Mol Sci. 2024;25:849.
    PubMed    
    Abstract available

  235. TATSUTA T, Ito J, Yamamoto K, Sugawara S, et al
    Sialidase NEU3 Contributes to the Invasiveness of Bladder Cancer.
    Biomedicines. 2024;12:192.
    PubMed    
    Abstract available

  236. LIU J, Tian C, Qiao J, Deng K, et al
    m6A Methylation-Mediated Stabilization of LINC01106 Suppresses Bladder Cancer Progression by Regulating the miR-3148/DAB1 Axis.
    Biomedicines. 2024;12:114.
    PubMed    
    Abstract available

  237. JEONG MS, Mun JY, Yang GE, Kim MH, et al
    Exploring the Relationship between CLPTM1L-MS2 Variants and Susceptibility to Bladder Cancer.
    Genes (Basel). 2023;15:50.
    PubMed    
    Abstract available

  238. UZELAC M, Xin R, Chen T, John D, et al
    Urinary Microbiome Dysbiosis and Immune Dysregulations as Potential Diagnostic Indicators of Bladder Cancer.
    Cancers (Basel). 2024;16:394.
    PubMed    
    Abstract available

  239. VERMA S, Swain D, Kushwaha PP, Brahmbhatt S, et al
    Melanoma Antigen Family A (MAGE A) as Promising Biomarkers and Therapeutic Targets in Bladder Cancer.
    Cancers (Basel). 2024;16:246.
    PubMed    
    Abstract available

  240. SUZUKI S, Gi M, Komiya M, Obikane A, et al
    Evaluation of the Mechanisms Involved in the Development of Bladder Toxicity following Exposure to Occupational Bladder Cancer Causative Chemicals Using DNA Adductome Analysis.
    Biomolecules. 2023;14:36.
    PubMed    
    Abstract available

  241. PORSERUD A, Karlsson P, Nygren-Bonnier M, Aly M, et al
    The feasibility of an exercise intervention after robotic-assisted radical cystectomy for urinary bladder cancer, prior to the CanMoRe trial.
    Pilot Feasibility Stud. 2024;10:12.
    PubMed    
    Abstract available

  242. MOUSAVIAN AH, Shafiee G, Sheidaei A, Balajam NZ, et al
    The 15-year national trends of urinary cancers incidence among Iranian men and women; 2005-2020.
    Int J Equity Health. 2024;23:13.
    PubMed    
    Abstract available

  243. OUYANG W, Xu R, Yao H, Jiang S, et al
    Urinary DNA methylation-based risk stratification model to triage patients for repeat transurethral resection of bladder tumours.
    Clin Transl Med. 2024;14:e1549.
    PubMed    


  244. VOLBERG C, Urhahn F, Pedrosa Carrasco AJ, Morin A, et al
    End-of-Life Care Preferences of Patients with Advanced Urological Malignancies: An Explorative Survey Study at a Tertiary Referral Center.
    Curr Oncol. 2024;31:462-471.
    PubMed    
    Abstract available

  245. LIU T, Ul-Haq W, Tang Q, Li W, et al
    Novel integrated Omics based computational approach for drug repurposing for non-muscle invasive bladder cancer (NMIBC).
    J Biomol Struct Dyn. 2024 Jan 21:1-11. doi: 10.1080/07391102.2024.2302343.
    PubMed    
    Abstract available

  246. TOMIYAMA E, Fujita K, Nonomura N
    [?. Urinary Liquid Biopsy in Bladder Cancer- Current Status and Issues].
    Gan To Kagaku Ryoho. 2024;51:40-44.
    PubMed    


  247. TANIGUCHI A, Hirakawa K, Mayama I
    [INFECTIOUS AORTITIS-RELATED MORTALITY AFTER ILEAL NEOBLADDER SUBSTITUTION IN A PATIENT WITH DIABETES MELLITUS].
    Nihon Hinyokika Gakkai Zasshi. 2023;114:26-29.
    PubMed    
    Abstract available

  248. KITA S, Yamakawa M, Kono R, Soumiya K, et al
    [NONRISING BLADDER PARAGANGLIOMA SUCCESSFULLY TREATED BY THE OPEN BLADDER SURGERY: A CASE REPORT].
    Nihon Hinyokika Gakkai Zasshi. 2023;114:16-20.
    PubMed    
    Abstract available

  249. WANG F, Zhang G, Xu T, Ma J, et al
    High and selective cytotoxicity of ex vivo expanded allogeneic human natural killer cells from peripheral blood against bladder cancer: implications for natural killer cell instillation after transurethral resection of bladder tumor.
    J Exp Clin Cancer Res. 2024;43:24.
    PubMed    
    Abstract available

  250. FU S, Tan Z, Shi H, Chen J, et al
    Development of a stemness-related prognostic index to provide therapeutic strategies for bladder cancer.
    NPJ Precis Oncol. 2024;8:14.
    PubMed    
    Abstract available

  251. LIU H, Wang X, Wu G, Wu J, et al
    PRPF19 could serve as a prognostic biomarker for patients with bladder cancer: A comprehensive analysis by integrating bulk and single-cell sequencing.
    Asian J Surg. 2024 Jan 19:S1015-9584(24)00115.
    PubMed    


  252. ASHLEY S, Choudhury A, Hoskin P, Song Y, et al
    Radiotherapy in metastatic bladder cancer.
    World J Urol. 2024;42:47.
    PubMed    
    Abstract available

  253. TYSON MD
    Single incision robotic cystectomy and urinary diversion.
    World J Urol. 2024;42:45.
    PubMed    
    Abstract available

  254. GALSKY MD, Daneshmand S, Izadmehr S, Gonzalez-Kozlova E, et al
    Author Correction: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.
    Nat Med. 2024 Jan 19. doi: 10.1038/s41591-024-02814.
    PubMed    


  255. MESSINA E, Proietti F, Laschena L, Flammia RS, et al
    MRI for risk stratification of muscle invasion by upper tract urothelial carcinoma: a feasibility study.
    Eur Radiol Exp. 2024;8:9.
    PubMed    
    Abstract available

  256. SHI J, Zhang K, Xiao T, Yang J, et al
    Exposure to disinfection by-products and risk of cancer: A systematic review and dose-response meta-analysis.
    Ecotoxicol Environ Saf. 2024;270:115925.
    PubMed    
    Abstract available

  257. SAHETIA KM, Dave VN, Pal M, Menon S, et al
    Clear cell urothelial carcinoma of bladder: Case report of a rare and aggressive variant with review of literature.
    Indian J Cancer. 2023;60:575-577.
    PubMed    
    Abstract available

  258. JI J, Liu T, Yao Y, Liu W, et al
    Characteristics and survival of primary urothelial carcinoma of the prostate: A multi-center retrospective study of 18 cases.
    Neoplasia. 2024;47:100961.
    PubMed    
    Abstract available

  259. MOLLICA V, Tassinari E, Santoni M, Marchese PV, et al
    TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab.
    Pathol Res Pract. 2024;253:155008.
    PubMed    
    Abstract available

  260. COBAN G, Yildiz P, Sahin N, Ersoz C, et al
    CD47 expression in urothelial carcinoma and its correlation with histopathological findings.
    Indian J Cancer. 2023;60:458-463.
    PubMed    
    Abstract available

  261. COPUR S, Yildiz AB, Covic A, Kanbay M, et al
    Is there any robust evidence showing that SGLT2 inhibitor predisposes to cancer?
    Eur J Clin Invest. 2024;54:e14131.
    PubMed    
    Abstract available

  262. ZHAO S, Li Y, Xu J, Shen L, et al
    APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
    Neurol Res. 2023 Nov 26:1-16. doi: 10.1080/01616412.2023.2287340.
    PubMed    
    Abstract available

  263. LI X, Zhang L, Hu S, Liu D, et al
    Postmarketing Safety of Sacituzumab Govitecan: A Pharmacovigilance Study Based on the FDA Adverse Event Reporting System.
    Clin Pharmacol Ther. 2024;115:256-268.
    PubMed    
    Abstract available

  264. DAI YN, Yi-Wen Yu E, Zeegers MP, Wesselius A, et al
    The Association between Dietary Inflammatory Potential and Urologic Cancers: A Meta-analysis.
    Adv Nutr. 2023 Nov 3:100124. doi: 10.1016/j.advnut.2023.
    PubMed    
    Abstract available

  265. WU Y, Cai D, Fan J, Meng C, et al
    An accurate diagnostic approach for urothelial carcinomas based on novel dual methylated DNA markers in small-volume urine.
    Chin Med J (Engl). 2024;137:232-234.
    PubMed    


  266. PACHECO RR, Pacheco R, Cooley C, Kaufman R, et al
    Diffuse Carbonic Anhydrase 9 and GATA3 Expression in Fumarate Hydratase Deficient Renal Cell Carcinoma - A Case Report and Immunoprofile Review.
    Int J Surg Pathol. 2024;32:145-149.
    PubMed    
    Abstract available

  267. CAO Q, Goldenberg M, Aron M, Wang T, et al
    Urinary Bladder "Melanosis": A Case Report and Review of the Literature.
    Int J Surg Pathol. 2024;32:104-108.
    PubMed    
    Abstract available

  268. YIM A, Alberto M, Sharma V, Green A, et al
    Near-infrared spectroscopy as a novel method of ex vivo bladder cancer tissue characterisation.
    BJU Int. 2024 Jan 18. doi: 10.1111/bju.16226.
    PubMed    
    Abstract available


  269. Significant advances in chemotherapy for both urothelial and renal cancer.
    BJU Int. 2024;133:122-123.
    PubMed    


  270. KLEMM J, Fisch M, Laukhtina E, Dahlem R, et al
    Continent diversion is losing its momentum: a nationwide trend analysis from Germany 2005-2021.
    BJU Int. 2024;133:154-157.
    PubMed    


  271. SU X, Jin K, Guo Q, Xu Z, et al
    Integrative score based on CDK6, PD-L1 and TMB predicts response to platinum-based chemotherapy and PD-1/PD-L1 blockade in muscle-invasive bladder cancer.
    Br J Cancer. 2024 Jan 11. doi: 10.1038/s41416-023-02572.
    PubMed    
    Abstract available

  272. PEIPERT JD, Chang J, Li S, di Pietro A, et al
    Reliability, validity, and change thresholds of the NCCN/FACT Bladder Symptom Index (NFBlSI-18) in patients with advanced urothelial cancer.
    Cancer. 2024;130:31-40.
    PubMed    
    Abstract available

  273. PETRYLAK DP, Eigl BJ, George S, Heath EI, et al
    Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma.
    Clin Cancer Res. 2024;30:63-73.
    PubMed    
    Abstract available

  274. YOLMO P, Siemens DR, Koti M
    Predicting Response in TIME and Space: Neoadjuvant Chemoimmunotherapy in Muscle-invasive Bladder Cancer.
    Eur Urol. 2023 Dec 23:S0302-2838(23)03296-7. doi: 10.1016/j.eururo.2023.
    PubMed    


  275. KIM SK, Byun YJ, Park SH, Piao XM, et al
    A 23-Gene Prognostic Index Predicts Progression and Bacillus Calmette-Guerin Response in Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2024 Jan 11:S0302-2838(24)00001-0. doi: 10.1016/j.eururo.2024.
    PubMed    


  276. PEDERZOLI F, Riba M, Venegoni C, Marandino L, et al
    Stool Microbiome Signature Associated with Response to Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Cancer.
    Eur Urol. 2024 Jan 5:S0302-2838(23)03341-9. doi: 10.1016/j.eururo.2023.
    PubMed    
    Abstract available

  277. NAOUN N, Loriot Y
    Towards Tailored Adjuvant Therapy in Bladder Urothelial Carcinoma: How Should We Fit Each Size?
    Eur Urol. 2024;85:123-124.
    PubMed    


  278. SRIDHAR SS, Powles T, Climent Duran MA, Park SH, et al
    Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance.
    Eur Urol. 2024;85:154-163.
    PubMed    
    Abstract available

  279. POWLES T, Assaf ZJ, Degaonkar V, Grivas P, et al
    Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma.
    Eur Urol. 2024;85:114-122.
    PubMed    
    Abstract available

  280. NAKAMOTO T, Yoshida T
    Response to Comment: Future goals of upper tract urothelial carcinoma endoscopic management.
    Int J Urol. 2024;31:90.
    PubMed    


  281. MORI K, Yanagisawa T, Fukuokaya W, Iwatani K, et al
    Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: A systematic review and network meta-analysis.
    Int J Urol. 2024;31:25-31.
    PubMed    
    Abstract available

  282. KIKUCHI E, Ng CF, Kitamura H, Ku JH, et al
    Controversies in terminology associated with management of BCG-unresponsive NMIBC in Asia-Pacific.
    Int J Urol. 2024;31:32-38.
    PubMed    
    Abstract available

  283. JUE JS, Alameddine M, Armenakas NA
    Future goals of upper tract urothelial carcinoma endoscopic management.
    Int J Urol. 2024;31:89.
    PubMed    


  284. UKIMURA O
    Editorial Comment on Does intensity-modulated radiation therapy by helical tomotherapy for prostate cancer increase the subsequent risk of bladder cancer? A propensity score-matched analysis.
    Int J Urol. 2024 Jan 10. doi: 10.1111/iju.15392.
    PubMed    


  285. TSUKUDA F, Tanaka Y, Narita S, Shimizu T, et al
    Does intensity-modulated radiation therapy by helical tomotherapy for prostate cancer increase the subsequent risk of bladder cancer? A propensity score-matched analysis.
    Int J Urol. 2024 Jan 9. doi: 10.1111/iju.15373.
    PubMed    
    Abstract available

  286. NAGAKAWA S, Shiota M, Takamatsu D, Tsukahara S, et al
    Clinical features and oncological outcomes of bladder cancer microsatellite instability.
    Int J Urol. 2024 Jan 9. doi: 10.1111/iju.15370.
    PubMed    
    Abstract available

  287. WU J, Cheng X, Yang H, Xiao S, et al
    Geriatric nutritional risk index as a prognostic factor in elderly patients with non-muscle-invasive bladder cancer: a propensity score-matched study.
    Int Urol Nephrol. 2024 Jan 4. doi: 10.1007/s11255-023-03905.
    PubMed    
    Abstract available

  288. SAITO T, Matsumoto K, Tanaka N, Fukumoto K, et al
    Prognostic impact of tumor ureteral invasion on recurrence after radical cystectomy.
    Int Urol Nephrol. 2024;56:129-135.
    PubMed    
    Abstract available

  289. KACZMAREK K, Plage H, Furlano K, Hofbauer S, et al
    Loss of Upk1a and Upk1b expression is linked to stage progression in urothelial carcinoma of the bladder.
    Int Urol Nephrol. 2024;56:499-508.
    PubMed    
    Abstract available

  290. BAHADORI A, Bray G, Rukin N
    Secondary tumours in orthotopic neobladder using isolated gut segment post radical cystectomy for urothelial carcinoma: a systematic review.
    Int Urol Nephrol. 2024;56:519-525.
    PubMed    
    Abstract available

  291. WANG S, Wei Z, Shu H, Xu Y, et al
    Early diagnosis and prognostic potential of RAC3 in bladder tumor.
    Int Urol Nephrol. 2024;56:475-482.
    PubMed    
    Abstract available

  292. WEISS K, Abimbola O, Mueller D, Basak R, et al
    Feasibility, Acceptability, and Outcomes of a Mobile Health Tool for Radical Cystectomy Recovery.
    J Urol. 2024;211:266-275.
    PubMed    
    Abstract available

  293. HOLZBEIERLEIN JM, Bixler BR, Buckley DI, Chang SS, et al
    Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment.
    J Urol. 2024 Jan 24:101097JU0000000000003846. doi: 10.1097/JU.0000000000003846.
    PubMed    
    Abstract available

  294. ZHOU F, Deng Z, Shen D, Lu M, et al
    DLGAP5 triggers proliferation and metastasis of bladder cancer by stabilizing E2F1 via USP11.
    Oncogene. 2024 Jan 5. doi: 10.1038/s41388-023-02932.
    PubMed    
    Abstract available

  295. CAI H, Ke ZB, Chen JY, Li XD, et al
    Ubiquitin-specific protease 5 promotes bladder cancer progression through stabilizing Twist1.
    Oncogene. 2024 Jan 13. doi: 10.1038/s41388-023-02936.
    PubMed    
    Abstract available

  296. REIKE MJ, Reicherz A, Tully KH, Bahlburg H, et al
    An empirical survey on the adaption of neoadjuvant chemotherapy in bladder cancer.
    Urol Int. 2024 Jan 19. doi: 10.1159/000536321.
    PubMed    
    Abstract available

  297. RICHARDS HL, Fortune DG, Lyons L, Curtin Y, et al
    Patients' emotional talk during surveillance cystoscopy for non-muscle invasive bladder cancer - opportunities for improving communication.
    Urology. 2023 Dec 29:S0090-4295(23)01116-0. doi: 10.1016/j.urology.2023.
    PubMed    
    Abstract available

  298. PETEINARIS A, Gkeka K, Katsakiori P, Tatanis V, et al
    Replicating Florence Intracorporeal Neobladder Technique in Laparoscopic Radical Cystectomy: A Retrospective Study.
    Urology. 2024;183:106-110.
    PubMed    
    Abstract available

  299. KIM AH, Ruel NH, Yamzon J, Zhumkhawala AA, et al
    Indiana Pouch Continent Cutaneous Urinary Diversion After Robotic-assisted Radical Cystectomy: A 16-Year Experience.
    Urology. 2024;183:e325-e327.
    PubMed    
    Abstract available

  300. JING S, Yang E, Luo Z, Zhang Y, et al
    Perioperative outcomes and continence following robotic-assisted radical cystectomy with mainz pouch II urinary diversion in patients with bladder cancer.
    BMC Cancer. 2024;24:127.
    PubMed    
    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.


;